Coda Genomics and Integrated Genomics entered into a collaboration to apply Coda’s Translation Engineering™ protein expression technology to the Pichia yeast expression system.
Robert J. Molinari, Ph.D., CEO of Coda, points out that translation engineering technologies address protein expression, solubility, and activity challenges in rational design steps at all stages of pharmaceutical development. “This utilization of synthetic biology can change the competitive landscape of many businesses, which rely on successful protein production,” he notes.
Integrated Genomics will provide the detailed genomic sequence of Pichia and other cell lines used in protein production. “The accurate sequence, assembly, and detailed annotation provided by Integrated Genomics allows Coda to provide enhanced genes for protein expression without amino acid changes in proteins of interest,” explains John Elling, Ph.D., president of Integrated Genomics.